WEIGHT & JOINTS
Weight, muscle, and your joints: why the scale is the wrong thing to watch
BMI hides the two things that actually matter for arthritis, and both respond to what you can do this month.
Week of July 31, 2026. Angelo Papachristos PT, ACPAC. RheumAcademy | Arthros Inc.
A woman in her late fifties came in with a knee that had been grinding for two years and a folded sheet of paper she kept in her purse: six months of weekly weigh-ins, the number barely moving. At a previous visit she had been told to lose twenty pounds before anything else was worth trying. She wanted to know if she was wasting her time.
The number that isn't the whole story
BMI is just weight divided by height squared. It cannot tell muscle from fat, and it cannot see where fat sits on your body. Two people at the same BMI can carry very different amounts of the metabolically active fat that drives inflammation and loads a joint.
This matters enormously for the people I see. If you are on prednisone for lupus or myositis, the scale climbs partly because of the drug and the fluid it holds, not because of anything you did at dinner. Being told to "just lose weight" in that situation lands as a moral judgment on a side effect.
The advice most patients get treats one number as the single lever. That framing is what I want to take apart, because it makes people feel like failures when the truth is that they are often measuring the wrong thing.
Two ways weight reaches your joints
The first route is mechanical, and it is real. In gait analysis of 142 adults with knee osteoarthritis, every pound lost took roughly four pounds of load off the knee with each step. That saving repeats thousands of times a day at the joint surface.
Mechanics cannot be the whole story, though. Carrying extra weight also tracks with hand osteoarthritis, at roughly twice the risk in a systematic review of 25 studies, and you do not walk on your hands.
That points to a second route. Fat tissue behaves like an active organ rather than inert padding, releasing inflammatory signalling molecules such as leptin. Laboratory work published in 2026, in human tissue samples and then in mice and cells, links leptin to abnormal blood vessel growth and remodelling in the bone beneath arthritic cartilage.
The clinic data run in the same direction. In rheumatoid arthritis, people with obesity are less likely to reach remission on the same treatment, with pooled odds about 40 percent lower across eight studies. In axial spondyloarthritis, a higher BMI tracks with higher disease activity scores.
So weight is not only about the mechanical load on one sore joint. It is feeding into the inflammatory system your treatment is trying to calm.
Muscle is doing more than you think
Here is the part BMI erases. Separate fat from muscle, and muscle keeps showing up as protective.
One 2026 study followed 769 women taking breast-cancer drugs that speed up bone loss. Women with more muscle had fewer spine fractures. Women whose body fat made up more than about 41 percent of their weight had roughly double the rate of new or worsening spine fractures, and bone density alone did not explain the gap.
A second 2026 study scanned 327 adults aged fifty and older. The more fat that had worked its way into the muscle, the worse the bone structure inside the spine. Again, this showed up beyond what the average bone-density reading captured.
This reframes the target. The goal is more muscle and less fat, which the scale can hide entirely because muscle is denser than fat.
The woman with the weigh-in sheet had been walking daily for six months. Her weight had barely moved, and she read that as failure. What she could not see was that she had almost certainly been holding onto leg muscle and function that protect the knee, and that quietly protect her bones for later.
She was not wasting her time. She was measuring the wrong outcome.
What losing weight actually does, and how much you need
For knee osteoarthritis, the strongest evidence comes from the IDEA trial (Messier and colleagues, JAMA 2013). Across 454 older adults with a painful knee and overweight or obesity, eighteen months of diet plus exercise produced less pain and better function than either diet alone or exercise alone.
A later analysis of that trial sorted people by how much they actually lost. More weight loss meant better pain, function, and walking distance, with the largest gains in those who lost 10 percent or more.
That makes five to ten percent a sensible first target rather than the finish line. Partial progress counts, and it counts more the further you get.
For people with obesity and knee osteoarthritis who have struggled with weight for years, the medication picture has changed. A 68-week trial published in the New England Journal of Medicine in 2024 (Bliddal and colleagues) tested weekly semaglutide against placebo, with diet and activity counselling in both groups. Weight fell by about 14 percent on semaglutide compared with about 3 percent on placebo, and knee pain improved more on the drug.
One caution keeps the emphasis where it belongs. In the DEMFOS trial, published in The Lancet Healthy Longevity in 2026, adding metformin to an intensive lifestyle program did nothing extra for physical function in 114 older adults with obesity and early frailty. The lifestyle work carried the entire benefit.
Whatever else you add, the movement and the muscle are doing the heavy lifting.
What's in your control, and what isn't
I want to be honest about the hard part. Sustained weight loss is genuinely difficult, and staying at a lower weight is harder still.
Some of what drives your weight is outside your hands: the steroids that control your disease, the pain that keeps you from moving, the fatigue of an active flare, your genetics. If a clinician has ever made you feel that your weight is simply a matter of willpower, they were wrong, and they were ignoring your medication list.
What you can influence is often the part that matters most. You can build and defend muscle with resistance training, even in small doses, even when the scale is stubborn. You can protect your joints and your future bone health that way regardless of what the number does.
A plateau on the scale while you keep training is not a stall. It is frequently the quiet success of trading fat for muscle.
What to do, and the conversation to have
Shift what you measure. Instead of a daily weigh-in, track a waist measurement, a strength marker like how many times you can stand from a chair in thirty seconds, and your pain during activity. Add resistance work two or three times a week and make sure you are eating enough protein to support it, because losing weight without protecting muscle is the outcome you least want. If you carry excess fat, aim for a realistic five to ten percent loss rather than a dramatic target.
Bring your medication list to the conversation. Ask your care team to set a target that accounts for steroids or other drugs that affect your weight, and ask specifically about a physiotherapy or exercise referral so the muscle side is not left to chance.
Questions for your care team
- Given my medications, especially any steroids, what is a realistic and safe weight or body-composition target for me?
- Can you refer me to physiotherapy or a supervised exercise program so I protect muscle while I work on my weight?
- If I have osteoarthritis and excess weight, am I a candidate for a GLP-1 medication like semaglutide, and how would it fit with my other drugs?
- Between visits, what should I track instead of the scale, for example waist size, a sit-to-stand count, and pain with activity?
What this does not mean
This is not a reason to stop or delay your prescribed DMARDs, biologics, or other disease treatment. Weight and muscle work sits on top of your medical treatment, never in place of it. And do not read a stalled scale as failure, because it often means you are trading fat for muscle, which is the goal.
References
Messier 2013 - IDEA trial, diet and exercise in knee OA. Messier SP, Mihalko SL, Legault C, et al. Effects of intensive diet and exercise on knee joint loads, inflammation, and clinical outcomes among overweight and obese adults with knee osteoarthritis: the IDEA randomized clinical trial. JAMA. 2013;310(12):1263-1273. doi:10.1001/jama.2013.277669
https://pubmed.ncbi.nlm.nih.gov/24065013/
Messier 2018 - how much weight loss is enough. Messier SP, Resnik AE, Beavers DP, et al. Intentional weight loss in overweight and obese patients with knee osteoarthritis: is more better? Arthritis Care Res (Hoboken). 2018;70(11):1569-1575. doi:10.1002/acr.23608
https://pubmed.ncbi.nlm.nih.gov/29911741/
Messier 2005 - weight loss and knee joint load. Messier SP, Gutekunst DJ, Davis C, DeVita P. Weight loss reduces knee-joint loads in overweight and obese older adults with knee osteoarthritis. Arthritis Rheum. 2005;52(7):2026-2032. doi:10.1002/art.21139
https://pubmed.ncbi.nlm.nih.gov/15986358/
Yusuf 2010 - weight and hand osteoarthritis. Yusuf E, Nelissen RG, Ioan-Facsinay A, et al. Association between weight or body mass index and hand osteoarthritis: a systematic review. Ann Rheum Dis. 2010;69(4):761-765. doi:10.1136/ard.2008.106930
https://pubmed.ncbi.nlm.nih.gov/19487215/
Liu 2017 - obesity and remission in rheumatoid arthritis. Liu Y, Hazlewood GS, Kaplan GG, Eksteen B, Barnabe C. Impact of obesity on remission and disease activity in rheumatoid arthritis: a systematic review and meta-analysis. Arthritis Care Res (Hoboken). 2017;69(2):157-165. doi:10.1002/acr.22932
https://pubmed.ncbi.nlm.nih.gov/27159376/
Liew 2020 - BMI and disease activity in axial spondyloarthritis. Liew JW, Huang IJ, Louden DN, Singh N, Gensler LS. Association of body mass index on disease activity in axial spondyloarthritis: systematic review and meta-analysis. RMD Open. 2020;6(1):e001225. doi:10.1136/rmdopen-2020-001225
https://pubmed.ncbi.nlm.nih.gov/32434828/
Bliddal 2024 - semaglutide in knee OA and obesity (STEP 9). Bliddal H, Bays H, Czernichow S, et al. Once-weekly semaglutide in persons with obesity and knee osteoarthritis. N Engl J Med. 2024;391(17):1573-1583. doi:10.1056/NEJMoa2403664
https://pubmed.ncbi.nlm.nih.gov/39476339/
DEMFOS 2026 - metformin plus lifestyle in older adults with obesity. Nava MLD, Viola V, Aguilar M, et al. Metformin added to lifestyle intervention for physical function in older adults with obesity (DEMFOS trial): a randomised controlled trial. Lancet Healthy Longev. 2026:100883. doi:10.1016/j.lanhl.2026.100883
https://pubmed.ncbi.nlm.nih.gov/42532077/
Schivardi 2026 - body fat, muscle mass, and spine fractures. Schivardi G, Cosentini D, Scartabellati G, et al. Adiposity excess and vertebral fractures in patients with breast cancer taking aromatase inhibitors. JAMA Netw Open. 2026;9(7):e2626450. doi:10.1001/jamanetworkopen.2026.26450
https://pubmed.ncbi.nlm.nih.gov/42530924/
Yi 2026 - muscle fat and vertebral bone quality. Yi M, Zhu S, Wang X, et al. Intramuscular fat infiltration is associated with higher vertebral void space burden and lower volumetric bone mineral density in older adults. Osteoporos Int. 2026. doi:10.1007/s00198-026-08162-8
https://pubmed.ncbi.nlm.nih.gov/42530584/
Li 2026 - leptin and subchondral bone in osteoarthritis. Li R, Xi Z, Luo S, Qin J, Liu T, Zhang J. Serum leptin exacerbates osteoarthritis by promoting subchondral bone H-type vessel angiogenesis via activation of the PI3K/AKT pathway. J Cell Mol Med. 2026;30(13):e71232. doi:10.1111/jcmm.71232
https://pubmed.ncbi.nlm.nih.gov/42374652/
This article is for education and general information only. It is not medical advice and cannot replace an assessment by your own rheumatologist or care team, who know your full history and medications. Do not change your treatment based on this piece without speaking to them first.
Angelo Papachristos PT, ACPAC. Advanced Practice Physiotherapist. Co-Founder, RheumAcademy. Co-Founder, Arthros Inc.